Home > Dermatology > Gut microbe curbs systemic inflammation in psoriasis

Gut microbe curbs systemic inflammation in psoriasis

EADV 2020
Reuters Health - 04/11/2020 - It may be possible to effectively treat systemic inflammation in psoriasis with a pill containing a single strain of a commensal gut microbe, according to results of a first-in-human, proof-of-concept study. The phase 1b study, by Evelo Biosciences, evaluated EDP1815, a non-live, pharmaceutical preparation of the human gut-derived commensal bacterium Prevotella histicola. "EDP1815 is not absorbed into the body, and it does not colonize the gut. Instead, its pharmacodynamic effect is through interactions with the immune cells within the small intestine - namely dendritic cells and macrophages - leading to coordinated downregulation of multiple inflammatory pathways, mimicking the body's normal physiological processes of inflammation resolution," study investigator Dr. Douglas Maslin, dermatologist and pharmacologist at Addenbrooke's Hospital in Cambridge, U.K., told Reuters Health by email. "In preclinical studies, EDP1815 is able...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on